Related references
Note: Only part of the references are listed.High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2014)
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission
Alessandro Armuzzi et al.
INFLAMMATORY BOWEL DISEASES (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L. S. Kiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
A.A. Fasanmade et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Monitoring Functional Serum Antitumor Necrosis Factor Antibody Level in Crohn's Disease Patients Who Maintained and Those Who Lost Response to Anti-TNF
Akihiro Yamada et al.
INFLAMMATORY BOWEL DISEASES (2010)
TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis
Trine Olsen et al.
CYTOKINE (2009)
Use of the Noninvasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis
James D. Lewis et al.
INFLAMMATORY BOWEL DISEASES (2008)
C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease
Chantal L. Koelewijn et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006
S. L. Jakobovits et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Predictors of early response to infliximab in patients with ulcerative colitis
Marc Ferrante et al.
INFLAMMATORY BOWEL DISEASES (2007)
Oratory markers in IBD: Magic, or unneccessary toys?
S Vermeire et al.
GUT (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Natalizumab induction and maintenance therapy for Crohn's disease
WJ Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
C-reactive protein as a marker for inflammatory bowel disease
S Vermeire et al.
INFLAMMATORY BOWEL DISEASES (2004)
Infliximab in moderately severe glucocorticoid resistant ulcerative colitis:: a randomised controlled trial
CSJ Probert et al.
GUT (2003)
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease
F Cornillie et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
Share Paper
